Illumina Reports the Acquisition of Fluent BioSciences to Expand its Multiomics Portfolio
Shots:
- Illumina has acquired Fluent BioSciences with cash on hand to expand its multiomics portfolio and enhance single-cell analysis & discovery. The financial terms were undisclosed and the acquisition was completed on Jul 9, 2024
- The acquisition adds Fluent's PIPseq V, which can identify cell types missed by conventional methods with the ability to process 100 to 1 million cells showing high scalability, to Illumina’s portfolio
- Illumina's sequencing & informatics technology, Partek Flow, will be integrated with Fluent's technology to offer a complete single-cell multiomic analysis solution, minimizing the need for complex instruments & consumables, making single-cell analysis more accessible & cost-effective
Ref: Illumina | Image: Illumina
Related News:- Veracyte Signs a Multi-Year Agreement with Illumina to Enhance its IVD Test for the Patients Globally
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
